Riding High On Investor Enthusiasm, BIO CEO 2014 Opens In New York
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s Chris Viehbacher says mutual respect, cultural understanding and close communication are keys to relationships with partners Alnylam and Regeneron; BIO survey confirms investor optimism for 2014; and RNAi panelists reflect on recent IPO glories.
You may also be interested in...
Day Two At BIO CEO: Deal Value Up, Deal Volume Down
The Let’s Make a Deal panel looked forward to more big product-focused Genzyme/Alnylam type deals in 2014 in a deal landscape changed by a robust pubic market and by caution on the part of big pharma; BIO chair Rachel King on 2014 priorities; Stallergenes prepares to launch Oralair
How And Why Genzyme And Alnylam Expanded Their Alliance
Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.
The Alnylam Turnaround: What Changed Investors’ Minds?
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.